Dociparstat sodium

N/A

Report date: 2024/04/29 20:00:40
NME

Base Information

Drug NameDociparstat sodium
Drug Alias NameODSHCX-01PGX-100PGX-ODSH-2013-AML-1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCathepsin G inhibitorsLeukocyte elastase inhibitorsP-selectin inhibitors +[6] 
TargetsCathepsin GLeukocyte elastaseP-selectin +[6] 
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Myelodysplastic SyndromesAcute Lung Injury +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesParingenix
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChimerix IncWashington University School Of MedicineCantex Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Myelodysplastic SyndromesAcute Lung Injury +[7] 

Other Information

ATC CodeN/A
Related LinksN/A